Vestor Capital LLC Has $26.60 Million Stock Holdings in Merck & Co., Inc. $MRK

Vestor Capital LLC boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 31,998.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 221,158 shares of the company’s stock after acquiring an additional 220,469 shares during the quarter. Merck & Co., Inc. accounts for about 1.9% of Vestor Capital LLC’s portfolio, making the stock its 17th largest position. Vestor Capital LLC’s holdings in Merck & Co., Inc. were worth $26,603,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Chesapeake Wealth Management increased its holdings in Merck & Co., Inc. by 0.6% in the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after purchasing an additional 87 shares during the period. South Plains Financial Inc. lifted its holdings in Merck & Co., Inc. by 0.6% during the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after buying an additional 89 shares during the period. Syverson Strege & Co grew its position in shares of Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock valued at $436,000 after buying an additional 90 shares during the last quarter. Nations Financial Group Inc. IA ADV increased its stake in shares of Merck & Co., Inc. by 0.4% in the first quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company’s stock valued at $2,819,000 after buying an additional 91 shares during the period. Finally, Westside Investment Management Inc. increased its stake in shares of Merck & Co., Inc. by 3.1% in the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after buying an additional 93 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Down 0.3%

Shares of Merck & Co., Inc. stock opened at $129.95 on Friday. The stock’s 50-day moving average is $123.02 and its 200 day moving average is $118.37. Merck & Co., Inc. has a one year low of $77.53 and a one year high of $135.05. The firm has a market cap of $320.96 billion, a price-to-earnings ratio of 36.61, a PEG ratio of 5.17 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the company posted $2.22 earnings per share. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Equities research analysts anticipate that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. CICC Research started coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective on the stock. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. BMO Capital Markets upped their price objective on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, Guggenheim increased their price objective on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Thirteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.50.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raised its price target on Merck from $140 to $150 and maintained an “overweight” rating, implying meaningful potential upside from recent trading levels. Barclays raises Merck price target
• Positive Sentiment: Erste Group modestly increased its fiscal 2027 EPS forecast to $9.54 from $9.52, signaling slightly stronger expectations for Merck’s longer-term earnings power. Erste Group raises Merck EPS estimate
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend supports the stock’s income appeal and represents an annualized yield of approximately 2.7%. Merck announces fourth-quarter dividend
• Positive Sentiment: A Merck-Wellcome joint venture is preparing doses of an experimental Ebola vaccine for clinical trials, providing a potential public-health and pipeline opportunity, although it is not an immediate earnings driver. Merck and Wellcome Ebola vaccine partnership
• Neutral Sentiment: Analysts expect second-quarter revenue of about $16.33 billion and a loss of $0.26 per share, with acquisition-related costs, Keytruda performance, and Gardasil demand likely to determine whether results beat or miss expectations. Merck second-quarter earnings preview
• Neutral Sentiment: Valuation analysis finds Merck attractive on discounted cash flow and cash-flow measures but more fairly valued based on earnings, suggesting further gains will require continued fundamental execution. Merck valuation analysis
• Negative Sentiment: Near-term uncertainty ahead of earnings—including acquisition costs and ongoing Gardasil challenges—may be weighing on sentiment despite expected strength from Keytruda. Merck earnings metrics preview

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.